RE:RE:RE:Vote No To Stock Split - Here's Why...I don't think Fred is that naive and yes he does care because it's investors he needs. He is looking to bring the remaining warrants and notes thru ammendments with having a more appealling less diluted share structure. Neovasc needs the U.S. market for the following reasons as is outlined in today's NR:
Consequences of a failure to effect a reverse stock split and remain on the Nasdaq
Management believes a failure to approve a reverse stock split and remain on the Nasdaq could have a material adverse effect on the Company and its stakeholders for several reasons, including the following:
- Liquidity in the trading of common shares of the Company (the "Common Shares") will be significantly reduced, as the Nasdaq is the Company's primary trading market, thereby putting downward pressure on the share price of the Common Shares.
- It will be more difficult for the Company to raise additional capital on reasonable terms from the majority of U.S. based institutional funds that require or want the Company to be listed on a major U.S. exchange in order to make an investment.
- The Company's US$28,575,000 aggregate amount of outstanding senior secured convertible notes (the "Notes") require the Company to be listed on the Nasdaq or a similar major U.S. exchange. Should the Company default on this requirement, the interest payable on the Notes will jump from 0% to 15% per annum, and holders of the Notes will receive a redemption right with a premium of 118% multiplied by the greatest closing price of the Common Shares during the period commencing on the date of delisting until the date such redemption payment is made.
Frankly, if the CEO wanted to sink the company then why bother with a strategic plan or do anything for that matter. Also, as for stock splits to have sudden drops is because of a lack of understanding about the process itself mainly from retail investors and hence the sell off, but this is usually the case for specific conditions particularly for biomed companies without any regulatory approvals and no revenue generating capacity. It is not uncommon for dilution in these spaces. Neovasc has both CE Mark and FDA giving the green light for Clinical trials and marketing, in other words significant upside potential. I'll say it again, the experts (analysts) still maintain a buy to strong buy rating on a number of fronts and sources.